Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 5/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | BRD2 | P25440 | 2/20 | 0.40 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.40 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL223427 | 1.00 | KDM4E (0.43) | KDM4EMAPTBRD4NOTUMBRD2 | |
| SCHEMBL223888 | 0.86 | NOTUM (0.48) | BRD4NOTUMBRD2BRD3PTGDR2 | |
| SCHEMBL222196 | 0.86 | NOTUM (0.48) | BRD4NOTUMBRD2BRD3PTGDR2 | |
| SCHEMBL223887 | 0.86 | NOTUM (0.48) | BRD4NOTUMBRD2BRD3PTGDR2 | |
| SCHEMBL222205 | 0.85 | BRD4 (0.45) | BRD4NOTUMBRD2BRD3PTGDR2 | |
| SCHEMBL222206 | 0.85 | BRD4 (0.45) | BRD4NOTUMBRD2BRD3PTGDR2 | |
| SCHEMBL222207 | 0.85 | BRD4 (0.45) | BRD4NOTUMBRD2BRD3PTGDR2 | |
| SCHEMBL15890945 | 0.84 | KDM4E (0.44) | KDM4EMAPTBRD4BRD2BRD3 | |
| SCHEMBL224909 | 0.84 | BRD4 (0.44) | BRD4NOTUMBRD2BRD3PTGDR2 | |
| SCHEMBL222198 | 0.84 | BRD4 (0.44) | BRD4NOTUMBRD2BRD3PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045423-B2 | Prophylactic and/or therapeutic agent for anemia comprising tetrahydroquinoline compound as active ingredient | KOWA COMPANY, LTD. (JP) | 2015-06-02 | — | — | US | disclosed |
| US-20140249144-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT | KOWA COMPANY, LTD. (JP) | 2014-09-04 | — | — | US | disclosed |
| US-8791090-B2 | Prophylactic and/or therapeutic agent for anemia comprising tetrahydroquinoline compound as active ingredient | KOWA COMPANY, LTD. (JP) | 2014-07-29 | — | — | US | disclosed |
| EP-2415764-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT | Kowa Company, Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120004197-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT | KOWA COMPANY, LTD. (JP) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249144-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT | EPOR, HBG1, HBG2 | KDM4E 1814/4885MAPT 4876/4885BRD4 861/4885 |
| US-20120004197-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT | EPOR, HBG1, HBG2 | KDM4E 1814/4885MAPT 4876/4885BRD4 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.